# US 2004/0018567 A1 · Modulators of B-lymphocyte activation, myosin-1F compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018567 A1
- Document ID: US20040018567A1
- Status: Published application
- Kind: A1
- Application number: 10/202,481
- Filed: 2002-07-23
- Published: 2004-01-29
- Earliest claimed: 2002-07-23
- Assignees: Rigel Pharmaceuticals, Inc.
- Inventors: Marcy K. Vallone; Brian R. Wong; Esteban Masuda; Mark Powell
- Web page: https://patentgrep.com/patent/US20040018567A1

## CPC

- C12Q 1/42: involving phosphatase
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- G01N 33/5052: {involving B-cells}
- G01N 33/9493: {Immunosupressants}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides compositions and methods for modulating B-lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating B-lymphocyte activation are provided. Compositions and methods for the treatment of disorders related to dysfunction or dysregulation of B-lymphocyte activation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating B-lymphocyte activation.

## Claims

### Claim 1

A method of screening for an immunosuppressant, comprising:
a) combining a candidate bioactive agent and a myosin-1F protein;
b) detecting modulation in the ATPase activity of said myosin-1F protein in the presence of said candidate bioactive agent;
c) contacting said candidate bioactive agent to a B-lymphocyte;
d) inducing activation of said lymphocyte; and
e) determining the activation of said lymphocyte in the presence of said candidate bioactive agent;
wherein said myosin-1F protein exhibits ATPase activity in the absence of said candidate bioactive agent, and wherein a decrease in the activation of said lymphocyte in the presence of said candidate bioactive agent indicates that said candidate bioactive agent is an immunosuppressant.

### Claim 2 (depends on 1)

The method of claim 1, wherein said myosin-1F protein comprises a myosin head domain and an amino acid sequence having at least about 95% identity to the amino acid sequence set forth in SEQ ID NO:2.

### Claim 3 (depends on 2)

The method of claim 2, wherein said myosin-1F protein comprises the amino acid sequence set forth in SEQ ID NO:2.

### Claim 4 (depends on 1)

The method of claim 1, wherein said myosin-1F protein comprises a myosin head domain but lacks a tail domain and consists essentially of an amino acid sequence having at least about 95% identity to the amino acid sequence set forth by amino acids 1-677, 19-677, 1-691, or 12-691 in SEQ ID NO:2.

### Claim 5 (depends on 4)

The method of claim 4, wherein said myosin-1F protein consists essentially of amino acids 1-677, 19-677, 1-691, or 12-691 in SEQ ID NO:2.

### Claim 6

A method of screening for an immunosuppressant, comprising:
a) combining a candidate bioactive agent, and an myosin-1F protein;
b) detecting binding of said myosin-1F protein to said candidate bioactive agent;
c) contacting said candidate bioactive agent to a B-lymphocyte;
d) inducing activation of said lymphocyte; and
e) determining the activation of said lymphocyte in the presence of said candidate bioactive agent;
wherein a decrease in the activation of said lymphocyte in the presence of said candidate bioactive agent indicates that said candidate bioactive agent is an immunosuppressant.

### Claim 7 (depends on 6)

The method of claim 6, wherein said myosin-1F protein comprises an amino acid sequence having at least about 95% identity to the amino acid sequence set forth in SEQ ID NO:2.

### Claim 8 (depends on 7)

The method of claim 7, wherein said myosin-1F protein comprises the amino acid sequence set forth in SEQ ID NO:2.

### Claim 9 (depends on 6)

The method of claim 6, wherein said myosin-1F protein comprises a myosin head domain but lacks a tail domain and consists essentially of an amino acid sequence having at least about 95% identity to the amino acid sequence set forth by amino acids 1-677, 19-677, 1-691, or 12-691 in SEQ ID NO:2.

### Claim 10 (depends on 9)

The method of claim 9, wherein said myosin-1F protein consists essentially of amino acids 1-677, 19-677, 1-691, or 12-691 in SEQ ID NO:2.

### Claim 11 (depends on 6)

The method of claim 6, wherein said myosin-1F protein comprises a tail domain but lacks a myosin head domain and consists essentially of an amino acid sequence having at least about 95% identity to the amino acid sequence set forth by amino acids 718-1098 in SEQ ID NO:2.

### Claim 12 (depends on 11)

The method of claim 11, wherein said myosin-1F protein consists essentially of amino acids 718-1098 in SEQ ID NO:2.

### Claim 13 (depends on 6)

The method of claim 6, wherein said myosin-1F protein comprises an IQ domain and a tail domain but lacks a myosin head domain and consists essentially of an amino acid sequence having at least about 95% identity to the amino acid sequence set forth by amino acids 695-1098 in SEQ ID NO:2.

### Claim 14 (depends on 13)

The method of claim 13, wherein said myosin-1F protein consists essentially of amino acids 695-1098 in SEQ ID NO:2.

### Claim 15

A method of screening for an immunosuppressant, comprising:
a) combining a candidate bioactive agent, a myosin-1F protein, and a myosin-1F binding partner;
b) detecting modulation of the binding of said myosin-1F protein to said myosin-1F binding partner in the presence of said candidate bioactive agent;
c) contacting said candidate bioactive agent to a B-lymphocyte;
d) inducing activation of said lymphocyte; and
e) determining the activation of said lymphocyte in the presence of said candidate bioactive agent;
wherein said myosin-1F protein will bind to said myosin-1F binding partner in the absence of said candidate bioactive agent, and wherein a decrease in the activation of said lymphocyte in the presence of said candidate bioactive agent indicates that said candidate bioactive agent is an immunosuppressant.

### Claim 16 (depends on 15)

The method of claim 15, wherein said myosin-1F protein comprises an amino acid sequence having at least about 95% identity to the amino acid sequence set forth in SEQ ID NO:2.

### Claim 17 (depends on 16)

The method of claim 16, wherein said myosin-1F protein comprises the amino acid sequence set forth in SEQ ID NO:2.

### Claim 18 (depends on 15)

The method of claim 15, wherein said myosin-1F protein comprises an IQ domain and a tail domain but lacks a myosin head domain and consists essentially of an amino acid sequence having at least about 95% identity to the amino acid sequence set forth by amino acids 695-1098 in SEQ ID NO:2.

### Claim 19 (depends on 18)

The method of claim 18, wherein said myosin-1F protein consists essentially of amino acids 695-1098 in SEQ ID NO:2.

### Claim 20 (depends on 15)

The method of claim 15, wherein said myosin-1F protein comprises a tail domain but lacks a myosin head domain and consists essentially of an amino acid sequence having at least about 95% identity to the amino acid sequence set forth by amino acids 718-1098 in SEQ ID NO:2.

### Claim 21 (depends on 20)

The method of claim 20, wherein said myosin-1F protein consists essentially of amino acids 718-1098 in SEQ ID NO:2.

### Claim 22 (depends on 15)

The method of claim 15, wherein said myosin-1F binding partner is selected from the group consisting of calmodulin, actin, BLNK, ATP, Arp2/3, Bee1p, WASP, WASP-IP, and Vrp1p.

### Claim 23 (depends on 15)

The method of claim 15, wherein said candidate bioactive agent is a small molecule chemical compound from about 200 to about 500 daltons in size.

### Claim 24 (depends on 1, 6)

The method of any of claims 1, 6, and 15, wherein inducing the activation of said B-lymphocyte is done by activating the B cell receptor (BCR).

### Claim 25 (depends on 1, 6)

The method of any of claims 1, 6, and 15, wherein determining the activation of said B-lymphocyte comprises determining the activity of the immunoglobulin heavy chain gene (IgH) promoter.

### Claim 26 (depends on 1, 6)

The method of any of claims 1, 6, and 15, wherein determining the activation of said B-lymphocyte comprises determining the expression of CD69.

### Claim 27 (depends on 1, 6)

The method of any of claims 1, 6, and 15, wherein a library of candidate bioactive agents is combined with said myosin-1F protein.

### Claim 28 (depends on 1, 6)

The method of any of claims 1, 6, and 15, wherein determining the activation of said B-lymphocyte involves sorting said lymphocyte by FACS.
